Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: cetirizine Clear all

Conditions: COVID-19
Interventions: Cetirizine, Famotidine, Cetirizine Placebo, Famotidine Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Multiple Sclerosis
Interventions: Cetirizine, Diphenhydramine; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Actinic Keratoses
Interventions: Antihistamine Cetirizine Hydrochloride, Placebo; Drug · Other
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Diego, California

Conditions: Allergic Conjunctivitis
Interventions: AC-170 0.05%, AC-170 0.1%, AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Neuromyelitis Optica
Interventions: cetirizine; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Normal Ocular Health
Interventions: AC-170 0.17%, AC-170 0.24% (Formulation 1), AC-170 0.24% (Formulation 2), Olopatadine hydrochloride 0.2%/Tears Naturale II; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Spinal Cord Injuries, Chronic Spinal Cord Injury, Subacute Spinal Cord Injury
Interventions: NVG-291, Placebo Injection; Drug
Lead sponsor: NervGen Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer
Interventions: L-NMMA; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Bethesda, Maryland • Houston, Texas

Conditions: Healthy
Interventions: Cetirizine HCl Tablets 10 mg, Zyrtec® Tablets 10 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Migraine
Interventions: PF-05180999, Placebo, 120 mg MR PF-05180999, 360 mg MR PF-05180999, 10 mg cetirizine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Submental Fat
Interventions: RZL-012, RZL-012+Lidacaine injection prior treatment, RZL-012+Medrol, RZL-012+Celecoxib+Zyrtec, RZL-012+facial and neck wrap; Drug
Lead sponsor: Raziel Therapeutics Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Manhattan, New York

Conditions: Oncology Patients Receiving Chemotherapy
Interventions: Cetirizine HCl 10 mg/mL, Diphenhydramine 50 mg/mL, anti-CD20 such as Rituximab or Paclitaxel; Drug
Lead sponsor: TerSera Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 7
States / cities: Napa, California • Rancho Mirage, California • Santa Rosa, California + 4 more

Conditions: Glycogen Storage Disease Type III
Interventions: UX053, Placebo, Antipyretic, H2 Blocker, H1 Blocker; Biological · Other · Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Orange, California • Atlanta, Georgia • Philadelphia, Pennsylvania + 1 more

Conditions: Healthy Subjects
Interventions: AC-170 0.24%, AC-170 Vehicle; Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Seasonal Allergic Rhinitis
Interventions: ACT-129968, Placebo, Cetirizine; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 12 Years to 76 Years
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more

Conditions: Allergic Conjunctivitis
Interventions: AC-150 Combo, AC-150A 0.1%, AC-150B 0.005%, Vehicle; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Acute Urticaria
Interventions: JDP-205 Injection, Diphenhydramine; Drug
Lead sponsor: JDP Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Cincinnati, Ohio • Columbus, Ohio

Conditions: Allergic Rhinitis, Asthma
Interventions: Cetirizine Hydrochloride 1 MG/ML, Placebo - Concentrate; Drug
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 6 Years to 20 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Pemphigus
Interventions: Ofatumumab, Acetaminophen/paracetamol, Antihistamine (cetirizine or equivalent), Prednisone/Prednisolone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • Ann Arbor, Michigan

Conditions: Pruritus
Interventions: Cetirizine, Placebo or sugar pill; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 6 Years to 18 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Seasonal Allergic Rhinitis
Interventions: fexofenadine HCl; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Allergic Conjunctivitis
Interventions: AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Allergic Rhinitis, Asthma
Interventions: Cetirizine, Placebo; Drug
Lead sponsor: California Allergy and Asthma Medical Group, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atopic Disease (Including Allergic Conjunctivitis)
Interventions: Drug: AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Andover, Massachusetts

Search by objective public record fields.

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project

A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

Neuromyelitis Optica (NMO) & Cetirizine

A Comparison of the Safety and Comfort of AC-170

NVG-291 in Spinal Cord Injury Subjects

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg

A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults

Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events

Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)

A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution

Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis

Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model

Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria

The Effect of Cetirizine on Bronchoconstriction

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching

Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

Study of Bronchodilation Effects of Cetirizine

A Multi-Center Study Evaluating the Safety of AC-170 0.24%